c-Met as a Target for Personalized Therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The HGF-MET signaling pathway plays crucial roles in physiological and pathological processes.
• Dysregulation of this pathway is implicated in cancer development and progression.
• MET signaling influences cell proliferation, survival, and invasion.

Purpose of the Study:

• To review the role of the HGF-MET signaling pathway in cancer.
• To summarize current therapeutic strategies targeting HGF-MET.
• To discuss the pathway's role in acquired resistance to targeted anticancer therapies.

Main Methods:

• Literature review of scientific articles on HGF-MET signaling in cancer.
• Analysis of downstream signaling pathways including MAPK, PI3K/AKT, STAT, and NF-κB.
• Examination of therapeutic agents targeting HGF and MET.

Main Results:

• HGF-MET signaling is a key oncogenic driver and a mechanism of resistance to EGFR and VEGFR inhibitors.
• Targeting HGF-MET with inhibitors shows therapeutic potential in various cancers.
• The pathway's involvement in resistance is evident in lung, kidney, and pancreatic cancers.

Conclusions:

• The HGF-MET pathway is a significant therapeutic target in oncology.
• Understanding HGF-MET signaling is critical for overcoming resistance to targeted cancer treatments.
• Further research into HGF-MET inhibitors may lead to improved cancer therapies.